Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication
Exploring the Influence of GLP-1 Medication on Food Attitudes and Selection in a Virtual Reality Buffet
Penn State University
25 participants
Jul 15, 2025
OBSERVATIONAL
Conditions
Summary
In recent years, GLP-1 medications have become a widely employed approach by physicians to address weight concerns in patients and lead to weight loss. Little is known, however, about how these medications may alter an individual's attitude towards food, food reactivity, or the specific types and amounts of foods an individual will choose. The purpose of this study is to observe the changes an individual experiences in their relationship and reaction to food and in their food selection prior to or within the first two weeks of taking GLP-1 medication to after three months on the medication. The researchers of this study believe that an understanding of such changes can inform questions seeking to ensure maintenance of appropriate nutrient balance within individuals on weight loss medications.
Eligibility
Inclusion Criteria5
- Adults (18+) with overweight or obesity (BMI \>25 kg/m2)
- Not currently taking an incretin-based medication at baseline
- Recently (within two weeks) prescribed a GLP-1, can be included if they have a obesity-related co-occurring condition (diabetes, hypertension, cardiovascular disease, dyslipidemia)
- Have had no prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
- Fluent in English
Exclusion Criteria7
- Adults (18+) without overweight or obesity
- \<18 years of age at time of testing
- Adults not taking a GLP-1 Medication
- Adults taking a compound GLP-1
- Adults on GLP-1 medication for longer than 2 weeks at baseline
- Have had a prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
- Not fluent in English
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
One visit before starting GLP-1 medication and one visit 3 months after. No other changes administered between visits.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06843512